

Linda Fiaschi, Sarah Craig, Lucy Bradshaw, Reuben Ogollah, Rachel Haines, Kate Walker, Jane Daniels  
Nottingham Clinical Trials Unit, University of Nottingham. United Kingdom

## Background

The GBS3 Trial (ISRCTN49639731), coordinated by the Nottingham Clinical Trials Unit (NCTU), assesses whether universal testing of pregnant women for Group B Streptococcus colonisation reduces early-onset neonatal sepsis, compared to the current UK risk-factor based strategy. Approximately 320,000 pregnant women from 80 maternity units in England, Scotland and Wales are needed for this cluster randomised trial. The testing policy becomes the standard of care for the duration of the trial and written informed consent for participation is not sought, to avoid selection bias.



## Method

Data provider security requirements create a two-step process to limit the release of personal identifiable information. The trial population is defined from maternity datasets through participating hospitals codes where women gave birth within the trial time window. Their babies are then identified by linkage and their identifiers used to request data from the microbiology and neonatal datasets.

All data is directly sent by each data provider to a Trusted Research Environment (TRE) where is safely stored and remotely processed, linked and analysed by designated analysts.

## Impact

Our approach, enabling a large study at lower cost, which is becoming increasingly popular in the clinical trial community, has the potential to inform future trials on the strengths and limitations of perinatal RCHD use in clinical trials.

